An underlying myeloproliferative disorder (MPD), especially polycythemia vera (PV) or essential thrombocythemia (ET), is a risk factor for thrombosis. Considering large selected studies, prevalence rates for major thrombosis, at time of diagnosis, range from $34 to 39% for PV and 10 to 29% for ET; the corresponding figures for thrombosis at follow-up are $8 to 19% for PV and 8 to 31% for ET. In all instances, arterial events were more frequent than venous events. In both PV and ET, advanced age and history of thrombosis are independent predictors of recurrent thrombosis. In addition, leukocytosis, but not thrombocytosis, has been identified as a potential risk factor for thrombosis in both diseases. The particular observation is consistent with the laboratory demonstration, in these disorders, of increased number of activated granulocytes and granulocyte-platelet aggregates, upregulation of platelet P-selectin and tissue factor expression by granulocytes, and the antithrombotic value of hydroxyurea therapy. Most recently, a JAK2 gain-offunction mutation (JAK2V617F) was described in virtually all patients with PV and $50% of those with ET. Whether the presence of this specific mutation or its allele burden modifies the risk of thrombosis in patients with MPDs currently is under investigation.
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More recently, another novel GOF mutation involving the thrombopoietin receptor (MPLW515L/K) was described in $1% of patients with ET and 5% of patients with PMF. 2, 3 JAK2V617F represents a G to T somatic mutation of JAK2, at nucleotide 1849, in exon 14, resulting in the substitution of valine to phenylalanine at codon 617. 4 MPLW515L mutation represents a G to T transition at nucleotide 1544, resulting in a tryptophan to leucine substitution at codon 515 of the transmembrane region of the MPL receptor. 2 Both JAK2V617F and MPLW515L have been shown to induce constitutive JAK-STAT activation as well as an MPD phenotype in mice. 2, [4] [5] [6] women are overrepresented in ET. 9, 10 Life expectancy is lower than normal in both disorders but significantly better in ET compared with PV, although median survival exceeds 15 years in both. [11] [12] [13] Causes of death include leukemic transformation (2 to 5% incidence in ET and 5 to 10% in PV in the first 15 years of the disease), consequences of fibrotic transformation, and thrombohemorrhagic complications.
14 Non-life-threatening complications include constitutional symptoms, superficial thrombophlebitis, minor mucocutaneous bleeding, increased propensity for first-trimester miscarriage, and microvascular disturbances (headaches, visual symptoms, lightheadedness, atypical chest pain, acral dysesthesia, and erythromelalgia). Among the latter symptoms, erythromelalgia is the most impressive but least prevalent, occurring in < 5% of patients. 15, 16 Table 1 (at diagnosis) 11,17-27 and Table 2 (during follow-up) 11,13,17-27 list incidence figures of major thrombotic events in a selected series of large studies in PV and ET. For comparison purposes, the tables also include incidence figures of bleeding and microvascular events. As is evident from these tables, there is some variation in reported incidence figures for major thrombosis at diagnosis that range from 9.7 to 29.4% for ET and 34 to 38.6% for PV; the corresponding figures for major thrombosis during follow-up are 8 to 30.7% for ET and 8.1 to 19% for PV. In almost all instances, arterial events were more prevalent than venous events, and thrombosis in general was more frequent than major bleeding. For example, in one recent study of 470 patients who experienced first thrombosis with either ET or PV, the event was arterial in 70% and venous in 30% of the patients. 28 Specifically, cerebrovascular accidents (CVAs) occurred in 184 cases (39%), coronary syndrome occurred in 102 cases (22%), lower extremity deep vein thrombosis (DVT) occurred in 102 cases (22%), and other DVT occurred in 40 cases (9%). 28 In addition, thrombosis is more relevant than bleeding as a cause of death in these disorders (Table 2) .
PREVALENCE OF THROMBOSIS IN ET AND PV
Although most of the variation in the aforementioned incidence figures is within legal statistical limits, some of the discrepancy is related to differences in definitions of what constitutes a major thrombotic event.
In this regard, most investigators consider strokes, transient ischemic attacks, myocardial infarctions, angina pectoris, peripheral artery occlusions, pulmonary embolism, and DVT as major thrombotic events. 11, 26, 29 In contrast, the association between superficial thrombophlebitis and DVT, if any, is too small to warrant its consideration as a major thrombotic event. 30 The same is true for erythromelalgia, which represents a separate platelet-vessel pathology that often responds to aspirin therapy. 15 DVT in MPDs includes sometimes catastrophic abdominal vein thrombosis (AVT), the incidence of which in ET was reported recently at 4% (19 cases among 469 consecutive patients with ET). 31 In another study of 501 patients with MPDs, including 23 cases of ET, 18 cases of AVT were identified and the diseasespecific rates were 10% for PV, 13% for ET, and 1% for CIMF. 32 The prevalence of MPD-associated AVT might be even higher because a substantial proportion of idiopathic AVT might represent latent MPD, as has been indicated recently by JAK2V617F mutational analysis of such cases. [33] [34] [35] Furthermore, ET-associated AVT has been shown to occur more frequently in young women and might predict a biologically more aggressive disease that is marked by inferior survival as well as a higher rate of leukemic transformation. 31 
PROGNOSTIC FACTORS FOR THROMBOSIS IN ET AND PV
In ET, two recent, large, single-institutional studies (n ¼ 322 and n ¼ 439, respectively) 11, 27 confirmed the previously well-established prothrombotic effect of advanced age (! 60 years) and history of thrombosis, although the latter association was significant with regard to arterial but not venous events in one of the two studies. 11 In addition, both studies identified leukocytosis (! 15 Â 10 9 /L in one study 11 and > 8.7 Â 10 9 /L in the other), 27 but neither thrombocytosis nor the presence of JAK2V617F, as an additional independent risk factor for thrombosis. Similarly, the presence of cardiovascular risk factors did not modify thrombosis risk in one of the two studies, 11 as well as in another recent study 28 involving 470 patients with either ET or PV who experienced firsttime thrombosis. 28 In the latter study, 34% of the patients experienced recurrent thrombosis, which was again predicted by age > 60 years and thrombosis history. 28 However, recurrence of either arterial or venous thrombosis depended on whether the first event was arterial or venous, respectively. 28 In PV, a series of reports from the European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) group have addressed multiple clinical issues including thrombotic complications. In their most recent report (n ¼ 1638), Landolfi et al, 36 on behalf of ECLAP, confirmed the strong association between advanced age and thrombosis and, in addition, identified leukocytosis (> 15 Â 10 9 /L as opposed to 10 Â 10 9 /L) as an independent predictor of myocardial infarction. History of arterial or venous events predicted recurrence of a similar vascular event. In contrast, neither the platelet count nor the hematocrit level affected thrombosis risk. In earlier reports, 26, 37 the ECLAP group had underscored the role of advanced age (age > 65 years), history of thrombosis, smoking, hypertension, and congestive heart failure as important predictors of new cardiovascular events. However, it is difficult to ascertain disease-specific risk from the presence of cardiovascular risk factors as opposed to expected risk that is adjusted for age, sex, and other relevant comorbidities. [38] [39] [40] Similarly, controlled prospective studies are needed to clarify the prognostic relevance of hereditary and acquired causes of thrombophilia, 39 pattern of X chromosome inactivation in granulocyte-derived DNA (i.e., monoclonal versus polyclonal), [41] [42] [43] [44] and altered polycythemia rubra vera-1 (PRV-1), platelet Mpl, or endogenous erythroid colonies (EEC) expression. 42 The above-described observations regarding the prognostic relevance of leukocytosis (but not thrombocytosis) in MPDs are consistent with the proven efficacy of hydroxyurea (but not anagrelide therapy) in high-risk ET. 29, 45 Hydroxyurea is a nonspecific myelosuppressive agent, whereas anagrelide is a relatively platelet-specific 
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cytoreductive agent. The particular observation is also consistent with the lack of increased risk for thrombosis associated with extreme thrombocytosis in otherwise low-risk ET. 46 Conversely, the series of retrospective studies performed by ECLAP in PV consistently have shown an antithrombotic effect for antiplatelet therapy. 36, 47 Furthermore, new evidence suggests that aspirin therapy in PV and ET might be most effective in preventing CVAs, whereas cytoreductive therapy and systemic anticoagulation might be needed to minimize the risk of coronary event and DVT, respectively.
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JAK2V617F AND THROMBOSIS
The association of JAK2V617F with PV (mutational frequency > 95%), ET (mutational frequency $50%), and CIMF (mutational frequency $50%), was first reported in 2005. 4, [48] [49] [50] Subsequently, the mutation has been demonstrated in other myeloid disorders including atypical MPDs (mutational frequency $20%) and myelodysplastic syndrome (mutational frequency < 5%). 51, 52 In vitro, JAK2V617F transforms cell lines by promoting JAK-STAT-mediated growth factor independency and/ or hypersensitivity. 53 In mice, the mutation induces PVlike disease that recapitulates most of the human disease characteristics except thrombocytosis. [4] [5] [6] Consistent with the latter observation, a significantly lower platelet count has been shown in JAK2V617F-positive as opposed to mutation-negative patients with ET.
23,54,55
JAK2V617F
has been traced to a primitive stem cell that is capable of erythroid-weighted trilineage myeloid differentiation, and clonal involvement of lymphocytes has been touted. 56, 57 Therefore, JAK2V617F probably contributes to a PV-weighted MPD phenotype, although it might not be the primary clonogenic event.
Among the original four reports on JAK2V617F, 4,48-50 two did not find an association between the presence of the mutation and thrombosis in ET, 48, 49 whereas one 50 had suggested otherwise in a group of MPD patients without providing information on specific disease associations. Subsequently, our group at the Mayo Clinic examined the relationship between the presence of JAK2V617F (mutation screening by polymerase chain reaction [lsqb]PCR[rsqb] sequencing), with regard to ET (n ¼ 150; mutational frequency 49%) 58 or JAK2V617F allele load with regard to PV (n ¼ 63; mutational frequency 92% and homozygous rate 21%), 59 and found no significant association with thrombosis in both instances. Other studies in ET, most of which used allele-specific PCR (AS-PCR) for mutation screening, yielded either the same or different conclusions (Table 3) . 23, 54, 55, 60, 61 For example, in the largest study reported to date, in ET (n ¼ 776; AS-PCR mutational frequency 53%), 23 the presence of JAK2V617F was associated with venous but not arterial thrombosis, although it was unclear if the particular association was sustained during a multivariable analysis that included covariates that are known to be significantly associated with JAK2V617F, including advanced age 23, 55, 58 and higher hemoglobin and leukocyte counts. 23, 54, 55, 58 In PV, the aforementioned study from our institution found that JAK2V617F homozygous patients displayed significantly higher hemoglobin level, neutrophil PRV-1 expression, and a propensity for both pruritus and fibrotic transformation. 59 These findings were confirmed recently by another study that used amplificationrefractory mutation system-PCR to measure JAK2V617F allele burden in 116 patients with PV (mutational frequency 83%; median value of allele load at 38%). 62 In addition, the latter 62 but not the former 59 study demonstrated an association between a high mutant allele burden and the degree of leukocytosis and splenomegaly, as well as increased thrombosis risk. 62 However, in another study of 397 PV patients, thrombosis risk, either at diagnosis or during follow-up, did not correlate with mutation profile (i.e., wild-type versus heterozygous versus homozygous). 63 Regardless, we believe that additional studies are required to clarify the relationship between thrombosis and JAK2V617F in the context of both arterial and venous thrombosis. It is also important to evaluate the effect of mutant allele burden among JAK2V617F-positive patients with ET as it pertains to thrombosis risk, as well as other disease complications.
LEUKOCYTOSIS AND THROMBOSIS IN MYELOPROLIFERATIVE DISORDERS
The aforementioned demonstration (see Prognostic Factors for Thrombosis in ET and PV) of a significant association between leukocytosis and thrombosis in both ET 11, 27 and PV 36 has provided additional evidence to support an ongoing concept regarding the role of granulocytes in MPD-associated thrombosis. 64 In this regard, specific mechanisms appear to involve cross-talk between granulocytes and platelets and/or endothelial cells. Compared with healthy controls, patients with ET or PV display increased baseline 65, 66 and induced (via thrombin and arachidonic acid) platelet P-selectin expression. 67 Patients compared to healthy controls also show increased platelet-granulocyte, [65] [66] [67] and platelet-monocyte 67 complexes. Granulocyte activation (increased CD11b, fibrinogen, leukocyte alkaline phosphatase but lower myeloperoxidase expression), [65] [66] [67] [68] [69] and baseline and lipopolysaccharide-induced expression of tissue factor (TF) by both monocytes 67 and neutrophils 65 is also increased in patients with PV or ET. Plasma evidence of endothelial damage and hypercoagulable state is also demonstrated in affected patients compared to controls. 68 Furthermore, these abnormalities might be more pronounced in patients with history of thrombosis and in those with JAK2V617F, according to some studies. 67, 69 Interestingly, a recent study suggested in vivo downregulation of both neutrophil TF expression and number of neutrophil-platelet complexes (but not platelet P-selectin expression) by hydroxyurea therapy in patients with either ET or PV. 65 This in vivo phenomenon was recapitulated in vitro, where hydroxyurea inhibited both P-selectin-mediated neutrophil TF expression and mixed aggregate formation in healthy subjects. 65 Earlier studies in healthy volunteers have shown P-selectin-mediated in vitro induction of TF synthesis and expression by neutophils. 70 In addition, in vitro induction of platelet-neutrophil complex formation is decreased in ET patients receiving aspirin therapy. 66 These observations provide additional novel mechanisms of action for both hydroxyurea and aspirin that might contribute to their proven efficacy in the treatment of high-risk patients with MPDs. 29, 45, 47 
CONCLUSIONS
The discovery of JAK2V617F, 4, [48] [49] [50] and more recently of other JAK2 mutations 71 and MPLW515L/K, 2,3 has brought MPDs into focus in terms of both translational research and integration of new information into current clinical practice. Primary caregivers already have incorporated mutation screening for JAK2V617F in their routine clinical practice for the evaluation of polycythemia, thrombocytosis, and unexplained abdominal vein thrombosis or bone marrow fibrosis. 72 However, the prognostic relevance of mutant allele burden, in terms of either thrombosis or other disease complications, currently is uncertain, and requires additional clarification. In this regard, application of precise and uniform diagnostic criteria and standardized PCR techniques for measurement of mutant allele burden are needed to allow valid interpretation of study results. Furthermore, prognostic utility, in terms of thrombosis risk, should be evaluated in a multivariable model that incorporates, at a minimum, age and thrombosis history as covariates. Finally, because high-risk patients with either ET or PV receive both cytoreductive and aspirin therapy, the therapeutic relevance of novel prognostic factors must be tested in low-risk patients as a separate group as well as in high-risk patients currently receiving optimal therapy. 
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